Table 1 The clinicopathologic characteristics of patients in the development cohort and the validation cohort
Variables | Development cohort (n = 131) | Validation cohort (n = 90) | P value |
|---|---|---|---|
Gender, male, n (%) | 117 (89.3%) | 70 (77.8%) | 0.032 |
Age [year, mean (IQR)] | 52.0 [46.0, 60.5] | 52.5 [45.0, 63.0] | 0.541 |
Hepatitis | |||
 NBNC, n (%) | 16 (12.2%) | 14 (15.6%) | 0.756 |
 HBV, n (%) | 113 (86.3%) | 75 (83.3%) | |
 HCV, n (%) | 2 (1.5%) | 1 (1.1%) | |
 NAFLD, n (%) | 5 (3.8%) | 6 (6.7%) | 0.521 |
 Cirrhosis, n (%) | 80.0 (61.1%) | 69.0 (76.7%) | 0.022 |
Resection type | |||
 Minor resection, n (%) | 44 (33.6%) | 34 (37.8%) | 0.619 |
 Major resection, n (%) | 87 (66.4%) | 56 (62.2%) | |
Lymph node dissection, n (%) | 19 (14.5%) | 21 (23.3%) | 0.134 |
Tumor number, multiple, n (%) | 34 (26.0%) | 25 (27.8%) | 0.884 |
Tumor size [cm, mean (IQR)] | 5.10 [3.60, 7.35] | 5.30 [3.03, 9.00] | 0.737 |
Tumor capsule, present, n (%) | 85 (64.9%) | 39 (43.3%) | 0.002 |
Microvascular invasion, n (%) | 77 (58.8%) | 64 (71.1%) | 0.083 |
Macrovascular invasion, n (%) | 23 (17.6%) | 31 (34.4%) | 0.007 |
Satellite nodules, n (%) | 48 (36.6%) | 28 (31.1%) | 0.480 |
Edmondson-Steiner classification | |||
 I/II, n (%) | 107 (81.7%) | 67 (74.4%) | 0.261 |
 III/IV, n (%) | 24 (18.3%) | 23 (25.6%) | |
RBC[10^12/L, mean (IQR)] | 4.63 [4.40, 4.92] | 4.74 [4.29, 5.12] | 0.615 |
Hb[g/L, mean (IQR)] | 143 [133, 150] | 145 [132, 155] | 0.781 |
PLT[10^9/L, mean (IQR)] | 175 [127, 235] | 180 [126, 216] | 0.994 |
Neutrophil count[10^9/L, mean (IQR)] | 3.77 [3.09, 4.76] | 3.97 [2.85, 5.36] | 0.116 |
Lymphocyte count [10^9/L, mean (IQR)] | 1.59 [1.16, 1.92] | 1.42 [1.15, 1.83] | 0.705 |
NLR[ratio, mean (IQR)] | 2.42 [1.74, 3.45] | 2.53 [1.66, 3.78] | 0.227 |
AST[U/L, mean (IQR)] | 39.4 [39.4, 126] | 34.5 [25.0, 58.0] | 0.133 |
PT[s, mean (IQR)] | 11.5 [11.0, 12.1] | 13.4 [12.8, 14.1] | < 0.001 |
TB[umol/L, mean (IQR)] | 13.3 [10.5, 18.1] | 7.00 [3.80, 12.1] | 0.870 |
ALB[g/L, mean (IQR)] | 41.4 [39.0, 44.5] | 39.5 [36.0, 42.8] | < 0.001 |
GGT[U/L, mean (IQR)] | 66.0 [33.5, 138] | 65.0 [42.0, 128] | 0.171 |
ALP[U/L, mean (IQR)] | 87.0 [69.5, 118] | 94.0 [74.3, 117] | 0.339 |
AFP[ng/mL, mean (IQR)] | 51.0 [7.95, 373] | 76.5 [9.13, 1540] | 0.250 |
CEA[ng/mL, mean (IQR)] | 2.50 [1.70, 3.70] | 2.86 [1.70, 4.40] | 0.725 |
CA19-9[U/mL, mean (IQR)] | 27.7 [13.8, 71.3] | 20.4 [10.2, 44.8] | 0.986 |
DCP[mAU/mL, mean (IQR)] | 64.0 [23.0, 412] | 110 [40.0, 940] | 0.057 |
Intraoperative blood loss [mL, mean (IQR)] | 200 [100, 300] | 200 [100, 288] | 0.105 |
Intraoperative blood transfusion, n (%) | 37 (28.2%) | 33 (36.7%) | 0.240 |
Child-Pugh | |||
 A, n (%) | 130 (99.2%) | 83 (92.2%) | 0.018 |
 B, n (%) | 1 (0.8%) | 7 (7.8%) | |
AJCC 8th | |||
 IA-II, n (%) | 111 (84.7%) | 71 (78.9%) | 0.347 |
 III-IV, n (%) | 20 (15.3%) | 19 (21.1%) | |